Journal of Neurology

, Volume 260, Issue 8, pp 2023–2032

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

Authors

    • Mellen Center U-10, Neurological InstituteCleveland Clinic
  • Frederik Barkhof
    • Image Analysis CenterVU University Medical Center
  • Giancarlo Comi
    • Department of NeurologyVita-Salute San Raffaele University
  • Guillermo Izquierdo
    • Department of NeurologyVirgen Macarena University Hospital
  • Bhupendra Khatri
    • St Luke’s Medical Center
  • Xavier Montalban
    • Department of Neurology-Neuroimmunology and CemcatVall d’Hebron University Hospital
  • Jean Pelletier
    • Department of Neurology and CRMBM CNRS7339CHU La Timone
  • Benjamin Eckert
    • Novartis Pharmaceuticals Corporation
  • Dieter A. Häring
    • Novartis Pharma AG
  • Gordon Francis
    • Novartis Pharmaceuticals Corporation
Original Communication

DOI: 10.1007/s00415-013-6932-0

Cite this article as:
Cohen, J.A., Barkhof, F., Comi, G. et al. J Neurol (2013) 260: 2023. doi:10.1007/s00415-013-6932-0

Abstract

In the 12-month phase 3 TRANSFORMS study, fingolimod showed greater efficacy than intramuscular interferon beta (IFNβ)-1a in patients with relapsing–remitting multiple sclerosis (RRMS). This study analyzed fingolimod efficacy compared with IFNβ-1a in patient subgroups from TRANSFORMS. Patients were randomized to receive fingolimod or weekly IM IFNβ-1a for 12 months. Analyses of efficacy included annualized relapse rate (ARR), and magnetic resonance imaging (MRI) measures [gadolinium (Gd)-enhancing T1 lesions, new/newly enlarged (active) T2 lesions, brain volume change]. Subgroups were defined based on demographics, disease characteristics (baseline EDSS score, relapse rate, and MRI parameters), and response to previous therapy. Fingolimod 0.5 mg reduced ARR over 12 months by 32–59 % relative to IFNβ-1a in all subgroups defined by demographic factors or baseline disease characteristics. Fingolimod also reduced the number of new Gd-enhancing lesions, active T2 lesions, and the rate of brain volume loss, versus IFNβ-1a in most (95 %) subgroups. In patients with high disease activity despite IFNβ treatment in the year before study, fingolimod 0.5 mg reduced ARR by 61 % relative to IFNβ-1a. Reductions in lesion counts and brain volume loss also favored fingolimod in these patients. In conclusion, consistently better efficacy was observed for fingolimod compared with IFNβ-1a across different subgroups of patients with RRMS.

Keywords

Multiple sclerosisRandomized clinical trialFingolimodInterferon-betaMRISubgroup analysis

Supplementary material

415_2013_6932_MOESM1_ESM.docx (875 kb)
Supplementary material 1 (DOCX 875 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2013